Literature DB >> 17047079

Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma.

Zhi-Zhang Yang1, Anne J Novak, Steven C Ziesmer, Thomas E Witzig, Stephen M Ansell.   

Abstract

The underlying mechanisms by which tumor cells are resistant to CTL-mediated apoptosis are not clear. Using a human model of B-cell non-Hodgkin's lymphoma (B-cell NHL), we show that intratumoral T(reg) cells inhibit the proliferation and granule production of activated autologous infiltrating CD8(+) T cells. Our results also show that degranulation and subsequent cytotoxic activity of infiltrating CD8(+) T cells exposed to lymphoma B cells is completely attenuated by the presence of intratumoral T(reg) cells. Furthermore, we show that increased numbers of intratumoral T(reg) cells correlates with the number of CD8(+) T cells in biopsy specimens from patients with B-cell NHL, supporting the in vitro findings that intratumoral T(reg) cells inhibit proliferation of infiltrating CD8(+) T cells. Taken together, these data indicate that human lymphoma B cells are sensitive to autologous CTL-mediated cell death but are protected by the inhibitory function of intratumoral T(reg) cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17047079      PMCID: PMC2680600          DOI: 10.1158/0008-5472.CAN-06-1822

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

1.  Dominant transplantation tolerance impairs CD8+ T cell function but not expansion.

Authors:  Chun-Yen Lin; Luis Graca; Stephen P Cobbold; Herman Waldmann
Journal:  Nat Immunol       Date:  2002-11-04       Impact factor: 25.606

2.  Control of regulatory T cell development by the transcription factor Foxp3.

Authors:  Shohei Hori; Takashi Nomura; Shimon Sakaguchi
Journal:  Science       Date:  2003-01-09       Impact factor: 47.728

3.  Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system?

Authors:  Bellinda A Bladergroen; Chris J L M Meijer; Rosita L ten Berge; C Erik Hack; Jettie J F Muris; Danny F Dukers; Andreas Chott; Yoshiaki Kazama; Joost J Oudejans; Oskar van Berkum; J Alain Kummer
Journal:  Blood       Date:  2002-01-01       Impact factor: 22.113

4.  Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome.

Authors:  S M Ansell; M Stenson; T M Habermann; D F Jelinek; T E Witzig
Journal:  J Clin Oncol       Date:  2001-02-01       Impact factor: 44.544

5.  Differentiation of anti-tumour cytotoxic T lymphocytes from autologous peripheral blood lymphocytes in non-Hodgkin's lymphomas.

Authors:  Laurence Chaperot; Olivier Manches; Jian Qing Mi; Agnes Moine; Marie-Christine Jacob; Rémy Gressin; Jean-Paul Molens; Jean-Jacques Sotto; Dominique Leroux; Jean-Claude Bensa; Joël Plumas
Journal:  Br J Haematol       Date:  2002-11       Impact factor: 6.998

6.  Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression.

Authors:  E M Sotomayor; I Borrello; F M Rattis; A G Cuenca; J Abrams; K Staveley-O'Carroll; H I Levitsky
Journal:  Blood       Date:  2001-08-15       Impact factor: 22.113

7.  Resistance to CD95-mediated apoptosis through constitutive c-FLIP expression in a non-Hodgkin's lymphoma B cell line.

Authors:  M Irisarri; J Plumas; T Bonnefoix; M C Jacob; C Roucard; M A Pasquier; J J Sotto; A Lajmanovich
Journal:  Leukemia       Date:  2000-12       Impact factor: 11.528

8.  A novel flow cytometric assay for quantitation and multiparametric characterization of cell-mediated cytotoxicity.

Authors:  H Lecoeur; M Février; S Garcia; Y Rivière; M L Gougeon
Journal:  J Immunol Methods       Date:  2001-07-01       Impact factor: 2.303

9.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.

Authors:  Jason D Fontenot; Marc A Gavin; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

10.  An essential role for Scurfin in CD4+CD25+ T regulatory cells.

Authors:  Roli Khattri; Tom Cox; Sue-Ann Yasayko; Fred Ramsdell
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

View more
  65 in total

1.  Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells.

Authors:  P Amé-Thomas; J Le Priol; H Yssel; G Caron; C Pangault; R Jean; N Martin; T Marafioti; P Gaulard; T Lamy; T Fest; G Semana; K Tarte
Journal:  Leukemia       Date:  2011-10-21       Impact factor: 11.528

Review 2.  The host-tumor interface in B-cell non-Hodgkin lymphoma: a new world to investigate.

Authors:  Nicolas Rachinel; Gilles Salles
Journal:  Curr Hematol Malig Rep       Date:  2009-10       Impact factor: 3.952

3.  Prognostic significance of T cell subsets in peripheral blood of B cell non-Hodgkin's lymphoma patients.

Authors:  Mehdi Dehghani; Shokouh Sharifpour; Zahra Amirghofran; Hamid Reza Zare
Journal:  Med Oncol       Date:  2012-02-04       Impact factor: 3.064

Review 4.  Microenvironment abnormalities and lymphomagenesis: Immunological aspects.

Authors:  Joseph G Taylor; John G Gribben
Journal:  Semin Cancer Biol       Date:  2015-07-29       Impact factor: 15.707

5.  Amphiregulin Confers Regulatory T Cell Suppressive Function and Tumor Invasion via the EGFR/GSK-3β/Foxp3 Axis.

Authors:  Sihua Wang; Yuan Zhang; Yan Wang; Ping Ye; Jun Li; Huabin Li; Qingqing Ding; Jiahong Xia
Journal:  J Biol Chem       Date:  2016-07-18       Impact factor: 5.157

Review 6.  Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials.

Authors:  Hyun Jun Park; Sattva S Neelapu
Journal:  Br J Haematol       Date:  2008-04-13       Impact factor: 6.998

7.  Follicular lymphoma B cells induce the conversion of conventional CD4+ T cells to T-regulatory cells.

Authors:  Weiyun Z Ai; Jing-Zhou Hou; Robert Zeiser; Debra Czerwinski; Robert S Negrin; Ronald Levy
Journal:  Int J Cancer       Date:  2009-01-01       Impact factor: 7.396

Review 8.  Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma.

Authors:  H Quach; D Ritchie; A K Stewart; P Neeson; S Harrison; M J Smyth; H M Prince
Journal:  Leukemia       Date:  2009-11-12       Impact factor: 11.528

9.  EBV infection determines the immune hallmarks of plasmablastic lymphoma.

Authors:  Pauline Gravelle; Sarah Péricart; Marie Tosolini; Bettina Fabiani; Paul Coppo; Nadia Amara; Alexandra Traverse-Gléhen; Nathalie Van Acker; Pierre Brousset; Jean-Jacques Fournie; Camille Laurent
Journal:  Oncoimmunology       Date:  2018-07-30       Impact factor: 8.110

10.  The role of regulatory T cells in cancer.

Authors:  Tai-You Ha
Journal:  Immune Netw       Date:  2009-12-31       Impact factor: 6.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.